| Click icon to automatically deliver podcasts to your iTunes or rich media player.
|
|
Explore the impact of health policy decisions, economic drivers and market developments on the specialty pharmaceutical market. Pharmaceutical Executive brings you this multi-part podcast series in partnership with AmerisourceBergen Specialty Group, the leading provider of specialty pharmaceutical product distribution and commercialization services.
Sponsored By AmerisourceBergen Specialty Group
|
| Trends in Patient Access: How Health Reform, Cost of Care and Stakeholder Response Will Shape Pharmaceutical Product Utilization
Questions abound over the impact that health reform and related measures will have on patients’ ability to receive the medications they want and need. |
Questions abound over the impact that health reform and related measures will have on patients’ ability to receive the medications they want and need.
Recorded 10.16.09
Click Here to Listen>>>
|
| The Future of Oncology: How Public Policy, New Technology and Financial Considerations will Impact Cancer Care |
With the U.S. healthcare system at an unprecedented crossroads, cancer care has emerged as one of the most hotly debated subjects. Stakeholders include manufacturers, physicians, patients, payers and service providers—even the government itself. And all have their own set of concerns to be addressed.
Recorded 08.24.09
Click Here to Listen>>>
|
| The Changing Relationship between Pharma and Managed Care |
Once viewed as the enemy, managed care has emerged as a necessary stakeholder and even a customer for pharmaceutical manufacturers and physicians in the specialty space. Join us as we discuss how this changing dynamic is impacting patient access, as well as product success.
Recorded 7.01.09
Click Here to Listen>>>
|
| Driving Product Success through Patient Adherence and Compliance |
Patient adherence and compliance programs can help manufacturers combat messaging from competing products, address patient concerns over the cost of care and reinforce the measurable benefit of a medication in the face of unpleasant side effects. Join us as we explore how patient adherence programs continue to evolve to meet manufacturer and patient needs. Hear real-world examples of how these programs can be integrated seamlessly into the continuum of care. Recorded 5.20.09
Click Here to Listen>>>
|
 |
| REMS: Is it the end of the world as we know it? (A two-part series) |
For manufacturers, do REMS represent a tremendous potential for confusion or an opportunity for growth? Join Pharmaceutical Executive Editor Joanna Breitstein as she sits down with Peyton Howell, President of Consulting Services and Health Policy for AmerisourceBergen Specialty Group, to address these critical issues in the first of this two-part series. Recorded 2.27.09
Click Here to Listen>>>
In the second installment of this two-part series, Pharmaceutical Executive’s Joanna Breitstein continues to explore the potential impact of new REMS programs with Jay Jackson, Senior Director for Healthcare Consultancy for Xcenda. They will discuss how REMS can create advantages for a product, what health outcomes data can be collected as part of REMS and what benefits REMS can offer to patients, providers and payers. Recorded 3.25.09
Click Here to Listen>>>
|
|
PharmExec Blog
Follow Us
RSS
Bookstore
